Novatreat Terminates Agreement With ImmuCell; ImmuCell Licenses Technology

Novatreat., Turku, Finland, has exercised its right to terminate the license and supply agreement it previously entered into with ImmuCell Corporation, Portland, ME, in March 2001. Novatreat, a licensee of certain nutritional rights of the company’s milk processing technology outside North America, has paid a $400,000 termination fee. It had previously paid the company $100,000 in license fees since entering into the agreement.

In other news, CURx Pharma, Evan­ston, IL, has entered into a separate li­cense agreement for ImmuCell’s DiffGAM technology. The license covers pharmaceutical rights to the company’s patented colonic delivery technology outside of Europe as well as certain nutritional rights in North America.